| Sep 26 |
EVAX Process Continues to Garner Interest and Investment
|
| Sep 26 |
Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024
|
| Sep 26 |
Merck & Co. Inc. (MRK): A Good Undervalued Blue Chip Stock to Buy According to Analysts
|
| Sep 25 |
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
|
| Sep 25 |
Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
|
| Sep 25 |
Merck fails in late-stage trial for Keytruda combo in colon cancer
|
| Sep 25 |
Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer
|
| Sep 25 |
Merck’s KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma
|
| Sep 25 |
Merck & Co., Inc. (MRK) Poised for 20% Gain, Analysts Say
|
| Sep 24 |
Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting
|
